Spryng for Equine

Storage

Spryng should be stored at room temperature with a range of 40°-90°F (5°-30°C). Use of Spryng particles is recommended within the expiration date stated on the package.

2. Intended Use and Indications for Use

Spryng microparticles promote restoration of proper joint mechanics by adding natural, viscosolid matrices to the joint’s synovial fluid. Spryng is indicated to aid in the management of noninfectious sources of joint pain including, but not limited to, degenerative joint disease, osteoarthritis, joint instability, and lameness.

3. Contraindications

Spryng is contraindicated in the following conditions:

● If there is a suspected infection in the intended joint or adjacent soft tissue or skin.

● If significant joint inflammation is present. If inflammation exists, prior effective treatment with anti-inflammatory agents is recommended.

4. Warnings

Do not inject Spryng intravascularly, as blood vessels may become occluded, infarcted, or emboli may form leading to life-threatening complications.

The use of this product in combination with other intra-articular medications has not been evaluated.

Not for use in humans.

Spryng has not been evaluated when combined with other intra-articular medications in one syringe or co-administered during a single procedure.

5. Precautions

Use Spryng with caution in horses with a previous history of hypersensitivity. Injection should be performed only by a licensed veterinarian skilled in the delivery of intra-articular (IA) injections.

6. Directions for Use

Spryng material is sterilized and aseptically filled in syringes containing 2 mL of material. It is intended for single-use, intra-articular injection (Figure 1). Use clinical judgement pertaining to volume needed. Some joints may require more or less than 2 mL of material. The amount of Spryng particles injected should represent an appropriate volume as determined by the veterinarian.

Preparation for Use

● Animal restraint and sedation is recommended.

● Thoroughly prep the area over the joint to be injected, following aseptic techniques in accordance with standard veterinary practices.

● Only the contents of the syringe are sterile. The exterior of the syringe is not sterile. Adjust technique accordingly.

Administration of Spryng

● Agitate the syringe to resuspend the particles homogeneously, ensuring ease of administration and accurate dosing.

● Administer intra-articularly using a sterile 19-25g needle.

● Apply even pressure on the plunger rod while injecting Spryng particles

● Volume injected may vary from 0.5 mL up to 4 mL, depending on species, joint, and joint capsule elasticity.

● Do not over-distend joints.

Additional Administration Information

● The injection technique, location, amount of synovial fluid removal, depth of injection, needle type, and the administered quantity of Spryng, may vary based on veterinarian clinical judgment and the joint selected.

● Multiple joints may be injected as a part of the same treatment.

● Additional administration of Spryng may be considered based on the veterinarian’s assessment. Field experience suggests the benefits of Spryng are long lasting and may extend beyond one year.

● A maximum annual administration frequency has not been established.

● If a syringe is only partially used, discard the unused portion. Each syringe is for a single use only. Do not use if the package is open or the syringe is damaged.

Disposal

The syringe and any unused material must be discarded after a single treatment visit. Follow national, local, or institutional guidelines for use and disposal of medical sharp devices.

7. Counseling for Owners

Reasonable expectations should be discussed with the owner prior to administration of Spryng regarding time to onset, duration, and level of improvement. Owners should be informed about post-administration NSAIDs, activity restrictions, contraindications, precautions, and potential complications. They should be encouraged to contact their veterinarian if unexpected signs occur.

8. Potential Adverse Reactions

Adverse events should be reported to PetVivo at 844-PET-VIVO (738-8486) or info1@petvivo.com

Some animals experience discomfort within the first 48 hours, similar to other intra-articular therapies. Animals may develop joint heat, effusion and/or lameness approximately 7 to 14 days post-administration. If not septic in origin, these events typically resolve within a few weeks with rest, cold therapy, NSAIDs, corticosteroid injection and/or systemic antimicrobials. Veterinarians should use their clinical judgement to determine whether delayed signs should be treated as a potentially septic joint.

MADE IN THE USA

Manufactured, marketed, and distributed by PetVivo, Inc., 5251 Edina Industrial Blvd., Minneapolis, MN 55439

844-PET-VIVO (738-8486)

www.petvivo.com

email: info1@petvivo.com

Spryng™ and OsteoCushion™ are trademarks of PetVivo Holdings, Inc.

This product is covered by U.S. Patent Nos. (US 8,153,591; US 9,107,937; US 9,999,705; US 10,850,006; CA 2,537,315; CA 2,583,561) and other pending applications and foreign patents. ©2024 PetVivo, Inc. All rights reserved.

SpryngHealth.com

youtube.com/@sprynghealth

TPD-3 Rev. 1/24

Presentation: 5 mL syringe with 2 mL of product.

CPN: 2127001.1